{
    "name": "Goodpasture Syndrome",
    "slug": "goodpasture-syndrome",
    "aliases": [
        "Anti-GBM Disease",
        "Goodpasture's Disease",
        "Pulmonary-Renal Syndrome with Anti-GBM Antibodies"
    ],
    "description": "Goodpasture syndrome is a rare autoimmune disorder characterized by the presence of circulating antibodies that attack the glomerular basement membrane (GBM) in the kidneys and the alveolar basement membrane in the lungs. This leads to rapidly progressive glomerulonephritis and pulmonary hemorrhage. Early diagnosis and treatment are crucial to prevent irreversible kidney damage and respiratory failure.",
    "category": "AUTOIMMUNE",
    "icdCode": "M31.0",
    "orphaCode": "79542",
    "omimCode": "233450",
    "prevalence": "Estimated at 1 in 1,000,000",
    "estimatedCases": 330,
    "ageOfOnset": "Most commonly affects individuals in their 20s or 60s, but can occur at any age.",
    "inheritance": "SPORADIC",
    "symptoms": [
        "Hemoptysis (coughing up blood)",
        "Dyspnea (shortness of breath)",
        "Fatigue",
        "Pallor (pale skin)",
        "Hematuria (blood in urine)",
        "Proteinuria (protein in urine)",
        "Edema (swelling)",
        "Hypertension (high blood pressure)",
        "Weight loss",
        "Chest pain"
    ],
    "affectedSystems": [
        "Renal (Kidneys)",
        "Respiratory (Lungs)",
        "Immune System"
    ],
    "prognosis": "Prognosis varies depending on the severity of the disease and the promptness of treatment. Early and aggressive treatment can lead to remission and prevent permanent organ damage. Without treatment, Goodpasture syndrome can be fatal due to kidney failure or respiratory failure.",
    "lifeExpectancy": "With prompt and effective treatment, life expectancy can be near normal. However, kidney damage may be irreversible in some cases, requiring long-term dialysis or kidney transplantation.",
    "diagnosticMethods": [
        "Anti-GBM antibody testing (blood test)",
        "Kidney biopsy",
        "Lung biopsy (if pulmonary involvement is unclear)",
        "Urinalysis",
        "Chest X-ray or CT scan"
    ],
    "treatmentOptions": [
        {
            "name": "Plasmapheresis",
            "type": "THERAPY",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Corticosteroids (e.g., Prednisone)",
            "type": "MEDICATION",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Immunosuppressants (e.g., Cyclophosphamide, Rituximab)",
            "type": "MEDICATION",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Dialysis",
            "type": "SUPPORTIVE",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Kidney Transplantation",
            "type": "SURGERY",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        }
    ],
    "researchStatus": "ACTIVE_TRIALS",
    "clinicalTrialsCount": 5,
    "keyResearchCenters": [
        "Mayo Clinic",
        "Johns Hopkins University",
        "National Institutes of Health (NIH)"
    ],
    "patientOrganizations": [
        {
            "name": "National Kidney Foundation",
            "url": "https://www.kidney.org/",
            "country": "USA"
        },
        {
            "name": "Vasculitis Foundation",
            "url": "https://www.vasculitisfoundation.org/",
            "country": "USA"
        }
    ],
    "relatedConditions": [
        "Systemic Lupus Erythematosus (SLE)",
        "Granulomatosis with Polyangiitis (GPA)",
        "Microscopic Polyangiitis (MPA)"
    ],
    "specialistTypes": [
        "Nephrologist",
        "Pulmonologist",
        "Rheumatologist",
        "Immunologist"
    ],
    "eli5Summary": "Imagine your body's defense system is confused and starts attacking your lungs and kidneys. Goodpasture syndrome is when this happens, causing bleeding in your lungs and damage to your kidneys. Doctors use special medicines to calm down your defense system and clean your blood to help you get better.",
    "clinicalSummary": "Goodpasture syndrome is a rare autoimmune disease characterized by the production of anti-GBM antibodies targeting type IV collagen in the glomerular and alveolar basement membranes. This leads to a rapidly progressive glomerulonephritis (RPGN) and pulmonary hemorrhage. The disease typically presents with hemoptysis, dyspnea, hematuria, and proteinuria. Diagnosis is confirmed by the presence of anti-GBM antibodies in serum and kidney biopsy showing linear IgG deposition along the GBM. Treatment involves plasmapheresis to remove circulating antibodies, corticosteroids, and immunosuppressants to suppress antibody production. Early diagnosis and aggressive treatment are essential to prevent irreversible kidney damage and respiratory failure. Long-term management may include dialysis or kidney transplantation in patients with end-stage renal disease.",
    "historicalBackground": "Goodpasture syndrome was first described by Ernest Goodpasture in 1919, who identified the association between pulmonary hemorrhage and glomerulonephritis in patients during the influenza pandemic. The autoimmune nature of the disease was later elucidated with the discovery of anti-GBM antibodies.",
    "recentBreakthroughs": [
        {
            "year": 2022,
            "title": "Rituximab as a Maintenance Therapy in Anti-GBM Disease",
            "description": "A study showed that rituximab maintenance therapy may reduce the risk of relapse in patients with anti-GBM disease who have achieved remission with initial treatment.",
            "sourceUrl": null
        },
        {
            "year": 2023,
            "title": "Novel Biomarkers for Predicting Renal Outcomes in Anti-GBM Disease",
            "description": "Research identified new biomarkers that can help predict the long-term renal outcomes in patients with anti-GBM disease, allowing for more personalized treatment strategies.",
            "sourceUrl": null
        }
    ],
    "heroImage": null,
    "diagrams": [],
    "lastUpdated": "2024-12-01",
    "reviewedBy": "MDRPedia Medical Team",
    "sources": [
        {
            "name": "National Institutes of Health (NIH)",
            "url": "https://www.nih.gov/"
        },
        {
            "name": "National Kidney Foundation",
            "url": "https://www.kidney.org/"
        },
        {
            "name": "Orphanet",
            "url": "https://www.orpha.net/"
        }
    ]
}